According to study data, every year around 30% of Americans aged 18+ make New Year’s resolutions, the highest proportion of which (49%) are aged between 18 and 29 (with 31% of 30-49 year-olds and 21% of 50+ adults also committing to some kind of annual improvement). Just over a third of those who decide on a yearly commitment to positive change aim to lose weight.
This study will look closely at the GLP-1 drugs used as part of weight loss plans, their cost, associated side effects, and the U.S. states in which weight loss drugs are most popular.
Before we look directly at the role of drugs in weight-loss programs, let’s consider a breakdown of the kinds of resolutions Americans make every New Year, and where weight loss lies in terms of resolution popularity.
New Year’s Resolutions: A Breakdown
Every new year in the U.S., millions of Americans set New Year’s resolutions as they bid to make an overdue improvement or jettison a bad habit. As the above data illustrates, much of that New Year focus centers on personal well-being, with healthy commitments among the most popular picks.
A striking 79% of people pledge to improve their overall health, aiming for long-term wellness as opposed to quick fixes or short-term trends. Within that broad category, boosting fitness levels emerges as a major priority for nearly half of all respondents, a choice driven by widely accessible exercise options and a desire to harness more daily energy, strength, and stamina.
Improving mental health is also popular, with over a third of goal-setters looking to enhance their emotional well-being. This trend underscores the evolving cultural shift of more openly addressing stress, burnout, and mental balance, and recognizing the importance of self-care.
Losing weight has long been a classic New Year’s resolution, with festive indulgence augmenting the urge to mark a new yearly cycle with a commitment to healthier eating and a new exercise regimen.
As previously mentioned, around a third of Americans yearly commit to losing weight, with better, less arduous mobility, and improved general long-term health among the incentives, beyond the obvious benefit of a shrinking waistline.
Healthy eating as a standalone objective is also popular, with almost a third of the population looking to adopt more balanced, nourishing diets for a more salubrious year ahead.
Overall, the data confirms that Americans head into the New Year resolutely committed to living and feeling better by strengthening both their physical and mental health. Rather than chase fleeting change, many look to build a healthier, more sustainable lifestyle to enhance the full upcoming year.
And when it comes to New Year’s weight loss resolutions, medication is an increasingly popular option for those looking to shed pounds.
Weight Loss: The Role of Medication
GLP-1 medications such as Ozempic and Wegovy are popular choices for Americans looking to tackle weight issues, with 1 in 8 or 12% of Americans having already tried GLP-1s to lose weight. GLP-1s are typically used to manage type 2 diabetes and support weight loss by helping to regulate blood sugar, lower appetite, and slow down digestion.
Search volume data from January through October 2025 reveals an evolving revolution regarding how Americans approach weight management, with GLP–1 medications increasingly popular.
Ozempic was the most popular sought-after term during the period in question, with over a million monthly searches. Ozempic interest initially surged during the January resolution season and maintained strong interest throughout the rest of the year.
Searches for GLP–1 also steadily rose, eventually surpassing 800,000 searches by the end of summer. By this point, public curiosity had expanded beyond brand names, with categories of medication also of keen interest.
Wegovy was subject to consistent interest throughout the year, a clear indication of its place as a major player in the weight-loss drug market.
Interest in Ozempic side effects was especially high at the start of the year, when new users and the GLP-1-curious were most likely to try and seek safety information. Thereafter, interest gradually decreased, suggesting growing consumer familiarity and confidence.
In contrast, searches for weight loss followed a predictable seasonal pattern: spiking sharply in January and again in March before dropping significantly through summer and fall. By the latter half of the year, searches for weight loss dwindled to numbers far lower than those for GLP-1s.
Overall, search habits emphasize a significant cultural and behavioral shift. Americans are increasingly turning their attention toward pharmaceutical slimming options, with GLP-1 medications now drawing far more interest than traditional dieting methods. The consistency and volume of searches for GLP-1s confirms that these medications have entered the dieting mainstream.
January GLP-1 Spikes
The timing of GLP-1 interest is telling. Search and prescription data indicate that GLP–1 curiosity spikes sharply in January, coinciding with New Year’s resolution season.
Google search volume data shows that searches for Ozempic increased by 40–60% at the start of the year, with early-year prescription rates simultaneously rising, suggesting that many adults are exploring pharmaceutical options as part of their resolution-driven commitments.
Younger adults show notably high interest, with polling indicating that adults under 50 are significantly more likely to try or contemplate the use of GLP-1 medications compared to older age groups.
GLP-1 use is currently highest among adults aged between 50 and 64 (22% of this age group actively use GLP-1s), with adults aged 65 and over using the drugs at much lower rates (9%), chiefly due to strict insurance coverage and medical eligibility requirements.
Younger adults are the fastest-growing demographic: in 2024, 7% of adults aged 18–29 and 6% of adults aged 30–49 specifically used a GLP-1 medication to lose weight.
Prescribing trends perfectly illustrate the rapid growth, with GLP-1 prescriptions among adults aged 18-39 increasing nearly 588% between 2019 and 2024, according to a national FAIR Health analysis.
Even among individuals diagnosed with diabetes, GLP-1 uptake rises in middle age. CDC data shows injectable GLP-1 use increases 25.3% among adults aged 18–34, and 33.3% among adults aged 50–64, before sharply declining among the over-65s.
Some Reasons for Weight Loss Medication Popularity
Surging interest in GLP-1 medication isn’t a quirk or a transient trend: it reflects a wide and permanent shift in how Americans think about health, weight loss, and long-term wellness. As obesity rates in the U.S. continually climb (CDC figures suggest persistent increases across nearly every demographic), more people are looking for a medical solution that offers meaningful and sustainable weight-loss results.
Clinical research has shown strong results from GLP-1 drugs like semaglutide and tirzepatide, with trials published in the New England Journal of Medicine demonstrating significant patient weight losses.
Such verified scientific outcomes have helped GLP-1 medications jettison the status of niche diabetes treatments and earn a position as a mainstream weight-management tool. Subsequent cultural visibility and cachet has augmented the momentum of GLP-1s.
Public conversations about prescription weight loss are now a social media norm, driven by influencers, celebrities, and everyday users who openly document their GLP-1 journey. This has shifted perceptions of medications like Ozempic, Wegovy, and Mounjaro, which no longer suffer the stigma of being considered purely ‘clinical interventions’ and are now widely accepted wellness tools.
Greater access has also played a major role. The expansion of telehealth and emergent digital health platforms has made it far easier for consumers to talk about and obtain GLP-1 medications, a change highlighted by McKinsey & Company market analysis.
On the medical side, FDA approval has broadened eligibility and helped normalize GLP-1 medications for people who previously struggled with traditional interventions. For example, the FDA prescription of Wegovy and Mounjaro information outlines the mechanisms and clinical evidence supporting their use for weight loss, and reinforces drug legitimacy for both clinicians and consumers.
Additionally, public attitudes toward obesity have shifted. People increasingly view weight management from a medical as opposed to a moral perspective, which has helped to destigmatize pharmaceutical obesity support.
The combination of scientific validation, cultural visibility, telehealth accessibility, and evolving health and obesity views mean GLP-1 medications are now a bona fide, influential wellness option.
However, that doesn’t mean everyone can afford to use GLP-1s.
Affordability and Access Disparities
As CBS reported, access to GLP-1s remains deeply uneven due to cost, insurance limitations, and employer benefit disparities. Historically, medications like Wegovy, Ozempic, and similar GLP-1s can cost up to $1,000 per month, putting them out of reach for many Americans.
Recent pricing adjustments and manufacturer discounts mean that, in some cases, a consumer may be able to get a GLP-1 for around $349 per month, but even at this rate, it may be too costly for individuals without strong insurance support.
Insurance plans also vary widely: while most cover GLP-1s for diabetes, they often exclude them for weight loss, creating strict barriers such as prior authorization, BMI requirements, and limited-duration approvals.
Employers are also experiencing rising healthcare costs, partly due to GLP-1 demand, leading some to tighten coverage criteria or reconsider long-term benefit strategies.
Although discount programs and telehealth offerings have expanded access, these options often benefit people with disposable income rather than those facing chronic health challenges or with inadequate insurance.
Overall, the data highlights a clear affordability divide. Those with strong insurance coverage or financial flexibility can readily access GLP-1 medications, while many lower-income, uninsured, or underinsured Americans remain priced out. This reinforces existing disparities regarding obesity treatment, chronic-disease prevention, and long-term health outcomes.
Moving on from individual coverage and access, let’s look at the states showing the most interest in GLP-1 drugs as weight loss aids.
Top 10 States: GLP-1 Weight Loss Interest
Search volume data (adjusted for population) provides a clear picture of GLP-1 interest, and related weight loss searches are most concentrated across the United States.
Virginia emerges as the clear leader, with approximately 934 searches per 100,000 residents, signaling exceptionally high engagement relative to its population size. This suggests not only strong public awareness of GLP-1 medications but also an active and ongoing curiosity about pharmaceutical weight loss options in the state.
Illinois and North Carolina follow closely behind, each generating more than 850 searches per 100,000 residents, confirming significant GLP-1 interest in the Midwest and Southeast. These two states represent a blend of large metro populations and suburban regions where weight loss medications have become a prominent part of public conversation.
Even in the largest states (California, New York, and Texas) high per-capita search rates prove that raw volume isn’t the only relevant factor. California and New York each surpass 800 searches per 100k residents, showing that interest in GLP-1 drugs extends beyond population-driven scale and reflects widespread familiarity across diverse communities.
Georgia, Florida, and Pennsylvania also maintain strong per-capita rates, illustrating consistent demand across the South and Mid-Atlantic regions.
Ohio, with a lower total population than some of the top-ranking states, rounds out the list with a rate of 738 searches per 100k, still significantly higher than the national baseline.
State search trends reveal that GLP-1 medications have captured attention across every major region of the country. Rather than interest being concentrated solely in large coastal markets, the highest per-capita search activity appears in a mix of Southern, Midwestern, and smaller Atlantic states, suggesting a countrywide shift toward pharmaceutical approaches to weight management.
This pattern also reflects broader social and cultural momentum around GLP-1 medications, signaling that interest is strong, sustained, and deeply embedded in public behavior across state demographics and geographic divides.
Yet, while GLP-1 drugs are now firmly established weight loss options, there are always side effects to consider.
GLP-1 Side Effects
GLP-1 medication side effects are varied, with gastrointestinal symptoms emerging as the most consistently reported issue. Nausea affects nearly half of GLP-1 users, making it the single most common reaction, while vomiting and abdominal discomfort follow closely as the body adjusts to slowed digestion and altered hunger cues.
The aforementioned symptoms are especially pronounced during the early weeks of treatment or when dosages increase. Metabolic changes also play a central role: reduced appetite is a routine feature of GLP-1s and a key driver of weight loss, while dehydration is a common secondary effect of nausea or decreased fluid intake.
Hormonal and digestive responses, such as delayed gastric emptying or acid reflux, further illustrate how GLP-1 medications influence the digestive system beyond simple appetite suppression.
Although many of these reactions are mild to moderate and improve over time, some users encounter significant complications. Gallbladder issues, including gallstones or inflammation, are linked to rapid weight loss and occur in a small but significant patient subset.
Rare but serious events such as pancreatitis or hypoglycemia can arise, particularly among individuals combining GLP-1s with other diabetes treatments. Injection-site reactions, like redness or itching, remain relatively uncommon and usually clear up on their own. Study data also highlights several extremely rare risks, including potential thyroid tumors, kidney injury related to dehydration, and severe allergic reactions.
While such events occur at extremely low rates, they reinforce the need for clinical monitoring and patient education. Ultimately, while GLP-1 medications are proven to be highly effective, they also represent a wide spectrum of associated side effects, highlighting the need for careful personalized care and ongoing oversight.
The GLP-1 Link to Deteriorated Mental Health
As GLP-1 usage grows, so does public curiosity about whether such medications affect mental health. Search trends show increasing interest in terms like Ozempic anxiety, GLP–1 depression, and mood changes, especially during the early months of the year when many new users begin treatment. These searches reflect a rising desire to understand both the physical and emotional effects of rapid appetite suppression and weight loss.
Current research, however, shows no clear evidence that GLP-1 medications increase depression or suicidal ideation. An extensive 2024 analysis in Nature Medicine found no association between semaglutide and elevated psychiatric risks. Many patients actually report emotional improvements as weight loss leads to better mobility, energy, and confidence.
That said, worries persist due to rare negative reports submitted to the FDA. In early 2024, the FDA began reviewing claims regarding mood changes among GLP-1 users (although the agency emphasized that no causal relationship was found, and current evidence suggests no widespread mental health risks).
Overall, while individual experiences vary, existing data indicates that GLP-1 medications are not linked to significant mental health harm, even as public interest and ongoing monitoring highlight the importance of continued research and evolving education.
GLP-1s as Preventers of Chronic Diseases
Study data does, however, suggest that GLP-1 medications may play a significant role not only in weight loss, but also in preventing or reducing the burden of chronic diseases that affect millions of Americans. Obesity is a major risk factor for conditions such as type 2 diabetes, hypertension, heart disease, and stroke, and the CDC notes that 42% of U.S. adults currently meet clinical criteria for obesity, a rate strongly linked to long-term cardiometabolic complications.
As a result, therapies that reduce weight and improve metabolic markers have the potential for substantial public-health impact.
A growing body of research supports this notion. One of the largest trials to date (the SELECT trial, published in The New England Journal of Medicine) found that semaglutide reduced the risk of major cardiovascular events by 20% in overweight or obese adults with existing heart disease (but without diabetes).
Additional studies show that GLP-1 drugs can improve blood pressure, reduce inflammation, lower A1c levels, and help delay or prevent the onset of type 2 diabetes in susceptible adults. The ADA also highlights semaglutide’s role in improving glycemic control and reducing the need for multiple diabetes medications, benefits that extend beyond weight loss.
Beyond diabetes and heart disease, new findings suggest GLP-1 medications may even help reduce liver fat and improve markers associated with nonalcoholic fatty liver disease, a condition that affects nearly one-third of U.S. adults.
Early research also indicates possible improvements in sleep apnea severity, mobility, and joint pain as patients lose weight and experience metabolic improvements.
Overall, the data shows that GLP-1 medications may cause multiple beneficial ripple effects far beyond weight reduction, potentially decreasing future healthcare costs, reducing chronic disease rates, and improving the long-term quality of life for millions of adults.
The Future of GLP-1s in America
As Americans head into the New Year, the data shows that people are redefining health, weight management, and long-term wellness. Although only about 30% of adults formally make New Year’s resolutions, nearly 79% of those who do set goals tied to improving their physical and mental health—signaling a nationwide desire for lasting, sustainable lifestyle change.
Search and prescription data indicate that GLP–1 curiosity spikes sharply in January, coinciding with New Year’s resolution season
Younger adults take the lead when it comes to setting resolutions, but interest in better fitness, emotional well-being, healthier eating, and weight loss encompasses every age. As such, GLP-1 medications like Ozempic and Wegovy have become one of the most influential forces shaping modern wellness culture.
Search activity for GLP-1 drugs rises sharply in January, outpacing conventional weight loss queries and reflecting a growing openness toward medicalized weight management. Throughout the year, GLP-1 terms consistently attract far more interest than traditional dieting searches, suggesting that the public increasingly views pharmaceutical tools as both legitimate and desirable.
Generational patterns reinforce this shift: while adults aged 50–64 currently show the highest usage rates, younger adults are adopting GLP-1s at a growing rate.
Prescription trends show a more than 500% increase among adults aged 18-39, and younger demographics are especially likely to turn to these medications for weight loss reasons.
At the same time, regional patterns reveal that GLP-1 adoption is widespread. States across the South, Midwest, Northeast, and West appear among the highest in per-capita search volume, with Virginia, Illinois, North Carolina, California, and Texas standing out as major hubs of interest. GLP-1 medications have clearly moved beyond niche communities or social media curiosity and into the U.S. mainstream.
However, access remains deeply unequal. Monthly costs, down from $1,000 a month to around $350 a month, are still beyond many Americans. Insurance coverage varies widely, with many plans excluding GLP-1s for weight loss, imposing strict eligibility criteria, or limiting eligibility periods. As a result, adults with high incomes, employer-sponsored insurance, or flexible budgets can far more easily obtain GLP-1s, reinforcing preexisting disparities in obesity treatment and chronic-disease prevention.
Despite these barriers, clinical research continues to show that GLP-1 medications have benefits far beyond weight loss alone. Large-scale studies demonstrate reduced cardiovascular events, improved metabolic health, and potential protection against conditions such as diabetes, fatty liver disease, sleep apnea, and chronic inflammation.
Public interest in side effects—especially nausea, vomiting, and digestive changes—peaks early in the year as new users begin treatment, and while concerns about mental health issues remain a prominent search topic, current evidence does not show a causal link between GLP-1 drugs and increased rates of depression or suicidal ideation.
Overall, the combined data clearly shows that Americans will enter the New Year highly motivated to improve their health, with GLP-1 medications now a central part of that effort.
The drugs have reshaped how people think about weight loss, expanded the boundaries of preventive medicine, and driven a cultural shift toward long-term, medically supported wellness strategies. With rising adoption across ages, regions, and lifestyles, GLP-1 medications will remain a defining public health factor for years to come.
Unfortunately, thousands of U.S. residents each year discover that the products they thought were safe and reliable are unsafe and dangerous. Although (as our study emphasizes) the likelihood is low, you may still suffer side effects while taking GLP-1 drugs.
Contact DeMayo Law Offices today for more information if you think we might be able to help.
